$BMY Recent Headlines
Post# of 145220
Posted On: 04/22/2014 12:13:38 PM
$BMY Recent Headlines
GlaxoSmithKline exits cancer drugs
8:36 a.m. Today8:36 a.m. April 22, 2014
- MarketWatch.com
Merck: Hepatitis C drug has 98% cure rate in trial
11:43 a.m. April 10, 2014
- MarketWatch.com
Market rookie Five Prime's shares surge on deal with Bristol-Myers
12:01 p.m. March 17, 2014
- Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike
5:19 p.m. March 4, 2014
- Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment
5:01 p.m. March 4, 2014
- Russ Britt
Billionaire Stan Druckenmiller's recent moves
12:50 p.m. Feb. 24, 2014
- Insider Monkey
Feds, pharma rivals team up on Alzheimer's
3:32 p.m. Feb. 6, 2014
- Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug
12:16 p.m. Jan. 27, 2014
- Russ Britt
U.S. stocks tumble; Dow drops 318 points
6:29 p.m. Jan. 24, 2014
- Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows
4:50 p.m. Jan. 24, 2014
- Sue Chang
U.S. stock futures trim losses ahead of market open
9:57 a.m. Jan. 24, 2014
- Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch
6:38 a.m. Jan. 24, 2014
- Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo
3:44 a.m. Jan. 22, 2014
- MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings
9:01 a.m. Jan. 19, 2014
- Wallace Witkowski
America's best and most generous 401(k)s
3:30 p.m. Jan. 15, 2014
- Anne Tergesen
Merck initiates melanoma filing with FDA
12:45 p.m. Jan. 13, 2014
- Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain
2:02 p.m. Jan. 8, 2014
- Russ Britt
Not all pharmaceuticals are created equal
1:40 p.m. Dec. 26, 2013
- The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper
1:06 p.m. Dec. 19, 2013
- Sara Sjolin
European stocks rally on Fed taper, rate views
1:00 p.m. Dec. 19, 2013
- Sara Sjolin
Glaxo Exits Cancer Drugs
8:19 a.m. Today8:19 a.m. April 22, 2014
- The Wall Street Journal Interactive Edition
Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff
4:23 p.m. April 21, 2014
- Seeking Alpha
AstraZeneca Shares Rise on Deal Speculation
4:08 p.m. April 21, 2014
- The Wall Street Journal Interactive Edition
Pfizer, AstraZeneca Rise On Report Of Merger Talks
10:13 a.m. April 21, 2014
- Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, XOM, MET
9:59 a.m. April 21, 2014
- TheStreet.com
J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
8:39 a.m. April 21, 2014
- 247WallSt.com
3 Stocks To Capitalize On Advances In Hepatitis C Treatment
8:31 a.m. April 21, 2014
- Seeking Alpha
Big Pharma Q1 Sales Hurt by Exchange Rates
11:34 a.m. April 17, 2014
- Barrons.com
3 Stocks Reiterated As A Buy: BMY, CELG, V
9:59 a.m. April 16, 2014
- TheStreet.com
3 Pharmaceuticals to Profit on Obamacare
6:34 a.m. April 16, 2014
- InvestorPlace.com
New Drug Cocktail Should Boost AbbVie Shares
2:29 p.m. April 15, 2014
- Barrons.com
Bristol-Myers files for HIV-1 combo drug
9:04 a.m. April 14, 2014
- Seeking Alpha
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?
8:07 a.m. April 14, 2014
- Wall St. Cheat Sheet
UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate
7:08 a.m. April 14, 2014
- benzinga.com
Cramer's Mad Money - 11 Things To Watch In The Week Ahead (4/11/14)
6:28 a.m. April 13, 2014
- Seeking Alpha
3 Stocks Reiterated As A Buy: BMY, LOW, CSCO
3:59 p.m. April 11, 2014
- TheStreet.com
Merck's Hepatitis C Drug May Boost Stock
11:09 a.m. April 11, 2014
- Barrons.com
Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks
8:51 a.m. April 11, 2014
- TheStreet.com
Investors: Brace for a Turbulent Second Quarter
1:07 p.m. April 10, 2014
- FOXBusiness
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients
7:05 a.m. April 10, 2014
- CNW Group
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
11:30 a.m. April 17, 2014
- PR Newswire - PRF
FluoroPharma Appoints Dr. H. William Strauss, Internationally
Recognized Expert in the Field of Cardiovascular Nuclear Medicine, to
Chair the Scientific Advisory Board
7:27 a.m. April 14, 2014
- Marketwire
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments
10:00 a.m. April 10, 2014
- PR Newswire - PRF
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
8:00 a.m. April 8, 2014
- PR Newswire - PRF
Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
12:34 p.m. April 7, 2014
- PR Newswire - PRF
Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to
US FDA for the Treatment of Hepatitis C
8:03 a.m. April 7, 2014
- BusinessWire - BZX
Theravance Appoints Kevin Kwok, Head of Talent Acquisition and
Strategy
4:05 p.m. April 1, 2014
- Marketwire
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on
April 29
9:00 a.m. April 1, 2014
- BusinessWire - BZX
Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer
10:22 a.m. March 31, 2014
- PR Newswire - PRF
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
1:50 a.m. March 31, 2014
- GlobeNewswire
In A Subanalysis, The Benefits Of Eliquis®
(apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With
Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood
Pressure Control 1
8:16 a.m. March 27, 2014
- BusinessWire - BZX
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
4:51 p.m. March 26, 2014
- PR Newswire - PRF
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
12:11 p.m. March 26, 2014
- PR Newswire - PRF
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
4:30 p.m. March 25, 2014
- GlobeNewswire
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
8:00 a.m. March 25, 2014
- PR Newswire - PRF
Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple
Investigational All-oral Combinations across Hepatitis C Genotypes at
The International Liver CongressTM
5:39 a.m. March 24, 2014
- BusinessWire - BZX
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx
8:00 a.m. March 21, 2014
- PR Newswire - PRF
Trace One Names Mark Martini as Vice President of North America to
Lead Sales and Customer Development
9:01 a.m. March 20, 2014
- BusinessWire - BZX
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
8:15 a.m. March 19, 2014
- GlobeNewswire
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
8:00 a.m. March 19, 2014
- PR Newswire - PRF
GlaxoSmithKline exits cancer drugs
8:36 a.m. Today8:36 a.m. April 22, 2014
- MarketWatch.com
Merck: Hepatitis C drug has 98% cure rate in trial
11:43 a.m. April 10, 2014
- MarketWatch.com
Market rookie Five Prime's shares surge on deal with Bristol-Myers
12:01 p.m. March 17, 2014
- Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike
5:19 p.m. March 4, 2014
- Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment
5:01 p.m. March 4, 2014
- Russ Britt
Billionaire Stan Druckenmiller's recent moves
12:50 p.m. Feb. 24, 2014
- Insider Monkey
Feds, pharma rivals team up on Alzheimer's
3:32 p.m. Feb. 6, 2014
- Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug
12:16 p.m. Jan. 27, 2014
- Russ Britt
U.S. stocks tumble; Dow drops 318 points
6:29 p.m. Jan. 24, 2014
- Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows
4:50 p.m. Jan. 24, 2014
- Sue Chang
U.S. stock futures trim losses ahead of market open
9:57 a.m. Jan. 24, 2014
- Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch
6:38 a.m. Jan. 24, 2014
- Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo
3:44 a.m. Jan. 22, 2014
- MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings
9:01 a.m. Jan. 19, 2014
- Wallace Witkowski
America's best and most generous 401(k)s
3:30 p.m. Jan. 15, 2014
- Anne Tergesen
Merck initiates melanoma filing with FDA
12:45 p.m. Jan. 13, 2014
- Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain
2:02 p.m. Jan. 8, 2014
- Russ Britt
Not all pharmaceuticals are created equal
1:40 p.m. Dec. 26, 2013
- The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper
1:06 p.m. Dec. 19, 2013
- Sara Sjolin
European stocks rally on Fed taper, rate views
1:00 p.m. Dec. 19, 2013
- Sara Sjolin
Glaxo Exits Cancer Drugs
8:19 a.m. Today8:19 a.m. April 22, 2014
- The Wall Street Journal Interactive Edition
Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff
4:23 p.m. April 21, 2014
- Seeking Alpha
AstraZeneca Shares Rise on Deal Speculation
4:08 p.m. April 21, 2014
- The Wall Street Journal Interactive Edition
Pfizer, AstraZeneca Rise On Report Of Merger Talks
10:13 a.m. April 21, 2014
- Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, XOM, MET
9:59 a.m. April 21, 2014
- TheStreet.com
J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
8:39 a.m. April 21, 2014
- 247WallSt.com
3 Stocks To Capitalize On Advances In Hepatitis C Treatment
8:31 a.m. April 21, 2014
- Seeking Alpha
Big Pharma Q1 Sales Hurt by Exchange Rates
11:34 a.m. April 17, 2014
- Barrons.com
3 Stocks Reiterated As A Buy: BMY, CELG, V
9:59 a.m. April 16, 2014
- TheStreet.com
3 Pharmaceuticals to Profit on Obamacare
6:34 a.m. April 16, 2014
- InvestorPlace.com
New Drug Cocktail Should Boost AbbVie Shares
2:29 p.m. April 15, 2014
- Barrons.com
Bristol-Myers files for HIV-1 combo drug
9:04 a.m. April 14, 2014
- Seeking Alpha
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?
8:07 a.m. April 14, 2014
- Wall St. Cheat Sheet
UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate
7:08 a.m. April 14, 2014
- benzinga.com
Cramer's Mad Money - 11 Things To Watch In The Week Ahead (4/11/14)
6:28 a.m. April 13, 2014
- Seeking Alpha
3 Stocks Reiterated As A Buy: BMY, LOW, CSCO
3:59 p.m. April 11, 2014
- TheStreet.com
Merck's Hepatitis C Drug May Boost Stock
11:09 a.m. April 11, 2014
- Barrons.com
Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks
8:51 a.m. April 11, 2014
- TheStreet.com
Investors: Brace for a Turbulent Second Quarter
1:07 p.m. April 10, 2014
- FOXBusiness
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients
7:05 a.m. April 10, 2014
- CNW Group
Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
11:30 a.m. April 17, 2014
- PR Newswire - PRF
FluoroPharma Appoints Dr. H. William Strauss, Internationally
Recognized Expert in the Field of Cardiovascular Nuclear Medicine, to
Chair the Scientific Advisory Board
7:27 a.m. April 14, 2014
- Marketwire
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments
10:00 a.m. April 10, 2014
- PR Newswire - PRF
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
8:00 a.m. April 8, 2014
- PR Newswire - PRF
Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
12:34 p.m. April 7, 2014
- PR Newswire - PRF
Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to
US FDA for the Treatment of Hepatitis C
8:03 a.m. April 7, 2014
- BusinessWire - BZX
Theravance Appoints Kevin Kwok, Head of Talent Acquisition and
Strategy
4:05 p.m. April 1, 2014
- Marketwire
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on
April 29
9:00 a.m. April 1, 2014
- BusinessWire - BZX
Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer
10:22 a.m. March 31, 2014
- PR Newswire - PRF
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
1:50 a.m. March 31, 2014
- GlobeNewswire
In A Subanalysis, The Benefits Of Eliquis®
(apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With
Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood
Pressure Control 1
8:16 a.m. March 27, 2014
- BusinessWire - BZX
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
4:51 p.m. March 26, 2014
- PR Newswire - PRF
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
12:11 p.m. March 26, 2014
- PR Newswire - PRF
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
4:30 p.m. March 25, 2014
- GlobeNewswire
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
8:00 a.m. March 25, 2014
- PR Newswire - PRF
Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple
Investigational All-oral Combinations across Hepatitis C Genotypes at
The International Liver CongressTM
5:39 a.m. March 24, 2014
- BusinessWire - BZX
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx
8:00 a.m. March 21, 2014
- PR Newswire - PRF
Trace One Names Mark Martini as Vice President of North America to
Lead Sales and Customer Development
9:01 a.m. March 20, 2014
- BusinessWire - BZX
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
8:15 a.m. March 19, 2014
- GlobeNewswire
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
8:00 a.m. March 19, 2014
- PR Newswire - PRF
(0)
(0)